First Time Loading...

Integral Diagnostics Ltd
ASX:IDX

Watchlist Manager
Integral Diagnostics Ltd Logo
Integral Diagnostics Ltd
ASX:IDX
Watchlist
Price: 2.47 AUD 1.23% Market Closed
Updated: May 10, 2024

Net Margin
Integral Diagnostics Ltd

-12.7%
Current
4%
Average
2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-12.7%
=
Net Income
-57.9m
/
Revenue
456.3m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
AU
Integral Diagnostics Ltd
ASX:IDX
576.6m AUD
-13%
US
Cigna Corp
NYSE:CI
98.8B USD
2%
US
Cigna Group
XMUN:CGN
92.4B EUR
2%
US
CVS Health Corp
NYSE:CVS
69.9B USD
2%
US
Laboratory Corporation of America Holdings
NYSE:LH
17.4B USD
4%
DE
Fresenius SE & Co KGaA
XETRA:FRE
16.1B EUR
-3%
US
Quest Diagnostics Inc
NYSE:DGX
15.3B USD
9%
DE
Fresenius Medical Care AG & Co KGaA
XETRA:FME
11.9B EUR
3%
DE
Fresenius Medical Care AG
XMUN:FME
11.4B EUR
3%
US
DaVita Inc
NYSE:DVA
12B USD
7%
US
Oak Street Health Inc
NYSE:OSH
9.5B USD
-24%
Integral Diagnostics Ltd
ASX:IDX
Country AU
Market Cap 576.6m AUD
Net Margin
-13%
Cigna Corp
NYSE:CI
Country US
Market Cap 98.8B USD
Net Margin
2%
C
Cigna Group
XMUN:CGN
Country US
Market Cap 92.4B EUR
Net Margin
2%
CVS Health Corp
NYSE:CVS
Country US
Market Cap 69.9B USD
Net Margin
2%
Laboratory Corporation of America Holdings
NYSE:LH
Country US
Market Cap 17.4B USD
Net Margin
4%
F
Fresenius SE & Co KGaA
XETRA:FRE
Country DE
Market Cap 16.1B EUR
Net Margin
-3%
Quest Diagnostics Inc
NYSE:DGX
Country US
Market Cap 15.3B USD
Net Margin
9%
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
Country DE
Market Cap 11.9B EUR
Net Margin
3%
Fresenius Medical Care AG
XMUN:FME
Country DE
Market Cap 11.4B EUR
Net Margin
3%
DaVita Inc
NYSE:DVA
Country US
Market Cap 12B USD
Net Margin
7%
Oak Street Health Inc
NYSE:OSH
Country US
Market Cap 9.5B USD
Net Margin
-24%

Profitability Report

View the profitability report to see the full profitability analysis for Integral Diagnostics Ltd.

Full Profitability Report

See Also

Summary
IDX intrinsic value, competitors valuation, and company profile.
DCF Valuation
IDX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
IDX stock valuation using valuation multiples.
Wall Street Estimates
IDX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
IDX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-12.7%
=
Net Income
-57.9m
/
Revenue
456.3m
What is the Net Margin of Integral Diagnostics Ltd?

Based on Integral Diagnostics Ltd's most recent financial statements, the company has Net Margin of -12.7%.

ALPHA SPREAD
Join more than 136,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.